GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) at the 2017 American Academy of Neurology Annual Meeting

News
1

These guys are one of 2 pharma companies investigating CBD for schizophrenia and other disorders.

The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. In the United States, GW operates as Greenwich Biosciences Inc.

3 Likes
2

God that would be so sweet. I love cannaboids but dont like thc. It makes getting high a love hate for me

1 Like